Abstract: The present invention relates to methods for identifying markers for systemic lupus erythematosus (SLE) and to the markers identified with the aid of this method, which can differentiate between SLE and other autoimmune diseases on the one hand and between different SLE subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in SLE. The invention also relates to methods for screening and validating active substances for application in SLE subgroups.
Type:
Grant
Filed:
July 6, 2020
Date of Patent:
January 2, 2024
Assignee:
Oncimmune Germany GmbH
Inventors:
Angelika Luking, Peter Schulz-Knappe, Carmen Theek, Petra Budde, Anna Telaar
Abstract: The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
March 21, 2023
Assignee:
ONCIMMUNE GERMANY GMBH
Inventors:
Petra Budde, Peter Schulz-Knappe, Angelika Luking, Martin Gamer
Abstract: Biomarkers are provided for predicting an irAE response associated with administration of anti-CTLA-4 antibodies (i.e. ipilumamb) and antibodies disrupting the PD-1/PD-L1 pathway (i.e. nivolumab or pembrolizumab) for treating melanoma. Methods of treatment incorporating such biomarkers are also provided.
Type:
Application
Filed:
December 10, 2018
Publication date:
July 29, 2021
Applicant:
ONCIMMUNE GERMANY GMBH
Inventors:
Petra BUDDE, Peter SCHULZ-KNAPPE, Hans-Dieter ZUCHT
Abstract: The present invention relates to methods for identifying markers for systemic lupus erythematosus (SLE) and to the markers identified with the aid of this method, which can differentiate between SLE and other autoimmune diseases on the one hand and between different SLE subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in SLE. The invention also relates to methods for screening and validating active substances for application in SLE subgroups.
Type:
Application
Filed:
July 6, 2020
Publication date:
February 25, 2021
Applicant:
Oncimmune Germany GmbH
Inventors:
Angelika LUKING, Peter SCHULZ-KNAPPE, Carmen THEEK, Petra BUDDE, Anna TELAAR
Abstract: The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.
Type:
Application
Filed:
December 4, 2019
Publication date:
January 7, 2021
Applicant:
Oncimmune Germany GmbH
Inventors:
Petra BUDDE, Peter SCHULZ-KNAPPE, Angelika LUKING, Martin GAMER
Abstract: The present invention relates to methods for identifying markers for systemic lupus erythematosus (SLE) and to the markers identified with the aid of this method, which can differentiate between SLE and other autoimmune diseases on the one hand and between different SLE subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in SLE. The invention also relates to methods for screening and validating active substances for application in SLE subgroups.
Type:
Grant
Filed:
February 10, 2015
Date of Patent:
August 18, 2020
Assignee:
Oncimmune Germany GmbH
Inventors:
Angelika Lüking, Peter Schulz-Knappe, Carmen Theek, Petra Budde, Anna Telaar